Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists

Abstract Crystallographic analysis of ligands bound to HDM2 suggested that 7-substituted 1,4-diazepine-2,5-diones could mimic the α-helix of p53 peptide and may represent a promising scaffold to develop HDM2–p53 antagonists. To verify this hypothesis, we synthesized and biologically evaluated 5-[(3 S )-3-(4-chlorophenyl)-4-[( R )-1-(4-chlorophenyl)ethyl]-2,5-dioxo-7-phenyl-1,4-diazepin-1-yl]valeric acid ( 10 ) and 5-[(3 S )-7-(2-bromophenyl)-3-(4-chlorophenyl)-4-[( R )-1-(4-chlorophenyl)ethyl]-2,5-dioxo-1,4-diazepin-1-yl]valeric acid ( 11 ). Preliminary in vitro testing shows that 10 and 11 substantially antagonize the binding between HDM2 and p53 with an IC 50 of 13 and 3.6 μM, respectively, validating the modeling predictions. Taken together with the high cell permeability of diazepine 11 determined in CACO-2 cells, these results suggest that 1,4-diazepine-2,5-diones may be useful in the treatment of certain cancers.